X0306 4 2022-09-01 0 0001831828 Vera Therapeutics, Inc. VERA 0001859453 Fordyce Marshall C/O VERA THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 120 BRISBANE CA 94005 1 1 0 0 President and CEO Class A Common Stock 2022-09-01 4 M 0 17100 2.8968 A 198250 D Class A Common Stock 2022-09-01 4 S 0 17100 21.2154 D 181150 D Class A Common Stock 2022-09-02 4 M 0 7346 2.8968 A 188496 D Class A Common Stock 2022-09-02 4 S 0 7346 20.2645 D 181150 D Class A Common Stock 2022-09-02 4 M 0 9750 2.8968 A 190900 D Class A Common Stock 2022-09-02 4 S 0 9750 21.4964 D 181150 D Stock Option (right to buy) 2.8968 2022-09-01 4 M 0 17100 0.00 D 2030-12-15 Class A Common Stock 17100 1073012 D Stock Option (Right to Buy) 2.8968 2022-09-02 4 M 0 17096 0.00 D 2030-12-15 Class A Common Stock 17096 1055916 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2022. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.69 to $21.675, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.00, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.01 to $21.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. /s/ Joseph R. Young, Attorney-in-Fact 2022-09-06